Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 99.54%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
99.54%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
+146.14%
vs the sector median at left
Black Diamond Therapeutics, Inc.
Market Cap
$107.44M
Gross Margin
99.54%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$108.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
2.35%
Market Cap
$108.38M
Gross Margin
46.49%
TTM Avg
23.25%
3Y Avg
11.62%
5Y Avg
7.75%
Market Cap
$106.68M
Gross Margin
83.37%
TTM Avg
83.81%
3Y Avg
82.64%
5Y Avg
80.50%
Market Cap
$105.20M
Gross Margin
71.67%
TTM Avg
77.09%
3Y Avg
79.04%
5Y Avg
77.65%
Market Cap
$104.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
5.83%
5Y Avg
8.02%
Market Cap
$110.12M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
Market Cap
$104.68M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | $107.44M | 99.54% | 0.00% | 0.00% | 0.00% |
| Immunic, Inc. (IMUX)vs › | $107.34M | 0.00% | 0.00% | 0.00% | 0.00% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.20M | 0.00% | 0.00% | 0.00% | 2.35% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.38M | 46.49% | 23.25% | 11.62% | 7.75% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.68M | 83.37% | 83.81% | 82.64% | 80.50% |
| Definitive Healthcare Corp. (DH)vs › | $105.20M | 71.67% | 77.09% | 79.04% | 77.65% |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.79M | 0.00% | 0.00% | 5.83% | 8.02% |
| Apyx Medical Corporation (APYX)vs › | $110.12M | 33.94% | 48.53% | 56.75% | 59.91% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | 0.00% | 0.00% | 0.00% | 0.00% |
| BGM Group Ltd. (BGM)vs › | $111.14M | 12.79% | 14.59% | 10.64% | 11.25% |
Gross Margin
99.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
